Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECI830 alone or with ribociclib and endocrine therapy in advanced HR-positive/HER2-negative breast cancer and advanced solid tumors
2024-517281-42-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, open-label trial of ECI830 in breast cancer, Nonhematologic neoplasms and small cell lung cancer (SCLC) (2 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability and 6-month progression-free survival rate. Planned start Nov 2025; status: authorised.
02
Drugs
ECI830
03
Conditions
breast cancerNonhematologic neoplasmssmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-517281-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517281-42-00.